Whilst it could be hypothesized that drugs targeting mostly lymphocytes are appropriate to treat typical SLE, drugs targeting the IFN pathway may have a major potential in the subgroup of normocomplementemic and inflammatory SLE. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.